Exploring Health Care Disparities in Genetic Testing and Research for Hereditary Cardiomyopathy: Current State and Future Perspectives

Abstract

Background Hereditary cardiomyopathies are commonly occurring myocardial conditions affecting heart structure and function with a genetic or familial association, but the etiology is often unknown. Cardiomyopathies are linked to significant mortality, requiring robust risk stratification with genetic testing and early diagnosis.
Hypothesis We hypothesized that health care disparities exist in genetic testing for hereditary cardiomyopathies within clinical practice and research studies.
Methods In a narrative fashion, we conducted a literature search with online databases such as PubMed/MEDLINE, Google Scholar, EMBASE, and Science Direct on papers related to hereditary cardiomyopathies. A comprehensive analysis of findings from articles in English on disparities in diagnostics and treatment was grouped into four categories.
Results Racial and ethnic disparities in research study enrollment and health care delivery favor White populations and higher socioeconomic status, resulting in differences in the development and implementation of effective genetic screening. Such disparities have shown to be detrimental, as minorities often suffer from disease progression to heart failure and sudden cardiac death. Barriers related to clinical genetic testing included insurance-related issues and health illiteracy. The underrepresentation of minority populations extends to research methodologies, as testing in ethnic minorities resulted in a significantly lower detection rate and diagnostic yield, as well as a higher likelihood of misclassification of variants.
Conclusions Prioritizing minority-based participatory research programs and screening protocols can address systemic disparities. Diversifying research studies can improve risk stratification strategies and impact clinical practice.

Keywords

hereditary cardiomyopathy / disparities / genetic testing / diversity / ethnic representation

References

[1] O'Mahony C, Jichi F, Pavlou M.et al; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35(30) 2010-2020

[2] Cadrin-Tourigny J, Bosman LP, Nozza A.et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2019; 40(23) 1850-1858

[3] Eberly LA, Day SM, Ashley EA.et al. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiol 2020; 5(01) 83-91

[4] Landry LG, Rehm HL. Association of racial/ethnic categories with the ability of genetic tests to detect a cause of cardiomyopathy. JAMA Cardiol 2018; 3(04) 341-345

[5] Manrai AK, Funke BH, Rehm HL.et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med 2016; 375(07) 655-665

[6] Griffith DM. Precision medicine approaches to health disparities research. Ethn Dis 2020; 30(Suppl. 01) 129-134

[7] Ciarambino T, Menna G, Sansone G, Giordano M. Cardiomyopathies: an overview. Int J Mol Sci 2021; 22(14) 7722

[8] Towbin JA. Inherited cardiomyopathies. Circ J 2014; 78(10) 2347-2356

[9] Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121(07) 749-770

[10] Bai Y, Zheng JP, Lu F.et al. Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China. Sci Rep 2022; 12(01) 18799

[11] Varma PK, Neema PK. Hypertrophic cardiomyopathy: part 1 - introduction, pathology and pathophysiology. Ann Card Anaesth 2014; 17(02) 118-124

[12] García-Castro M, Coto E, Reguero JR.et al. [Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy]. Rev Esp Cardiol 2009; 62(01) 48-56

[13] Viswanathan SK, Sanders HK, McNamara JW.et al. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage. PLoS One 2017; 12(11) e0187948

[14] Ku L, Feiger J, Taylor M, Mestroni L. Familial Cardiomyopathy Registry. Cardiology patient page. Familial dilated cardiomyopathy. Circulation 2003; 108(17) e118-e121

[15] Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: a translational review of current literature. J Intern Med 2019; 286(04) 362-372

[16] Dellefave L, McNally EM. The genetics of dilated cardiomyopathy. Curr Opin Cardiol 2010; 25(03) 198-204

[17] Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017; 390(10092): 400-414

[18] Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol 2016; 68(25) 2871-2886

[19] Rapezzi C, Aimo A, Barison A.et al. Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J 2022; 43(45) 4679-4693

[20] Morales A, Hershberger R, Chapter 56—Genetic testing. In: Jefferies JL. et al., eds. Heart Failure in the Child and Young Adult. Boston: Academic Press;; 2018: 743-748

[21] Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121(07) 819-837

[22] Neagoe O, Ciobanu A, Diaconu R, Mirea O, Donoiu I, Militaru C. A rare case of familial restrictive cardiomyopathy, with mutations in MYH7 and ABCC9 genes. Discoveries (Craiova) 2019; 7(03) e99

[23] van der Voorn SM, Te Riele ASJM, Basso C, Calkins H, Remme CA, van Veen TAB. Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy. Cardiovasc Res 2020; 116(09) 1571-1584

[24] Maron MS, Rowin EJ, Olivotto I.et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2016; 67(12) 1399-1409

[25] McKoy G, Protonotarios N, Crosby A.et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355(9221) 2119-2124

[26] Ross SB, Jones K, Blanch B.et al. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. Eur Heart J 2020; 41(14) 1428-1436

[27] Finsterer J, Stöllberger C, Towbin JA. Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors. Nat Rev Cardiol 2017; 14(04) 224-237

[28] Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet 2015; 386(9995) 813-825

[29] Pérez-Serra A, Toro R, Sarquella-Brugada G.et al. Genetic basis of dilated cardiomyopathy. Int J Cardiol 2016; 224: 461-472

[30] Kimura A. Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J Hum Genet 2010; 55(02) 81-90

[31] Chen SN, Mestroni L, Taylor MRG. Genetics of dilated cardiomyopathy. Curr Opin Cardiol 2021; 36(03) 288-294

[32] Tadros R, Francis C, Xu X.et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet 2021; 53(02) 128-134

[33] Pirruccello JP, Di Achille P, Nauffal V.et al; BioBank Japan Project. Genetic analysis of right heart structure and function in 40,000 people. Nat Genet 2022; 54(06) 792-803

[34] Aung N, Lopes LR, van Duijvenboden S.et al. Genome-wide analysis of left ventricular maximum wall thickness in the UK biobank cohort reveals a shared genetic background with hypertrophic cardiomyopathy. Circ Genom Precis Med 2023; 16(01) e003716

[35] Garnier S, Harakalova M, Weiss S.et al. Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. Eur Heart J 2021; 42(20) 2000-2011

[36] Liu CF, Ni Y, Thachil V, Morley M, Moravec CS, Tang WHW. Differential expression of members of SOX family of transcription factors in failing human hearts. Transl Res 2022; 242: 66-78

[37] Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res 2021; 128(10) 1533-1553

[38] Melas M, Beltsios ET, Adamou A, Koumarelas K, McBride KL. Molecular diagnosis of hypertrophic cardiomyopathy (HCM): in the heart of cardiac disease. J Clin Med 2022; 12(01) 225

[39] Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol 2022; 19(03) 151-167

[40] Gyftopoulos A, Chen YJ, Wang L.et al. Identification of novel genetic variants and comorbidities associated with ICD-10-based diagnosis of hypertrophic cardiomyopathy using the UK biobank cohort. Front Genet 2022; 13: 866042

[41] Chintanaphol M, Orgil BO, Alberson NR, Towbin JA, Purevjav E. Restrictive cardiomyopathy: from genetics and clinical overview to animal modeling. Rev Cardiovasc Med 2022; 23(03) 108

[42] Sunkak S, Kiraz A, Argun M, Erdoğan İ. Restrictive cardiomyopathy with ring chromosome 6 anomaly in a child. Anatol J Cardiol 2021; 25(10) 745-746

[43] Fu J, Sun DM, Zhang Y, Huang YF, He Q, Zhang J. [A case of restrictive cardiomyopathy associated with new TPM1 gene mutation]. Zhonghua Er Ke Za Zhi 2022; 60(10) 1077-1078

[44] Odak M, Douedi S, Mararenko A.et al. Arrhythmogenic right ventricular cardiomyopathy: the role of genetics in diagnosis, management, and screening. Cardiol Res 2022; 13(04) 177-184

[45] Kyriakopoulou E.et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat Cardiovasc Res 2023; 2(12) 1262-1276

[46] Nagueh SF, Bhatt R, Vivo RP.et al. Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure. Circ Cardiovasc Imaging 2011; 4(03) 220-227

[47] Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr 2009; 10 (08) iii15-iii21

[48] Assomull RG, Prasad SK, Lyne J.et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48(10) 1977-1985

[49] Corrado D, Perazzolo Marra M, Zorzi A.et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020; 319: 106-114

[50] Adabag AS, Maron BJ, Appelbaum E.et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51(14) 1369-1374

[51] Mathew J, Zahavich L, Lafreniere-Roula M.et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet 2018; 93(02) 310-319

[52] Papadopoulou E, Bouzarelou D, Tsaousis G.et al. Application of next generation sequencing in cardiology: current and future precision medicine implications. Front Cardiovasc Med 2023; 10: 1202381

[53] Di Marco A, Brown PF, Bradley J.et al. Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2021; 77(23) 2890-2905

[54] Køber L, Thune JJ, Nielsen JC.et al; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375(13) 1221-1230

[55] Del Mestre E, Pio Loco Detto Gava C, Paldino A.et al. Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy. Eur Heart J Suppl 2023; 25(Suppl B): B144-B148

[56] Stafford F, Thomson K, Butters A, Ingles J. Hypertrophic cardiomyopathy: genetic testing and risk stratification. Curr Cardiol Rep 2021; 23(02) 9

[57] Cimiotti D, Budde H, Hassoun R, Jaquet K. Genetic restrictive cardiomyopathy: causes and consequences-an integrative approach. Int J Mol Sci 2021; 22(02) 558

[58] Liu Y, Chen H, Shou W. Potential common pathogenic pathways for the left ventricular noncompaction cardiomyopathy (LVNC). Pediatr Cardiol 2018; 39(06) 1099-1106

[59] Gatzoulis KA.et al. The role of genetics in risk stratification strategy of dilated cardiomyopathy. Rev Cardiovasc Med 2022;23(09):

[60] Sheikh N, Papadakis M, Panoulas VF.et al. Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. Heart 2016; 102(22) 1797-1804

[61] Arabadjian ME, Yu G, Sherrid MV, Dickson VV. Disease expression and outcomes in black and white adults with hypertrophic cardiomyopathy. J Am Heart Assoc 2021; 10(17) e019978

[62] Burns J, Jean-Pierre P. Disparities in the diagnosis of hypertrophic obstructive cardiomyopathy: a narrative review of current literature. Cardiol Res Pract 2018; 2018: 3750879

[63] Coughlin SS. Toward the primary prevention of idiopathic dilated cardiomyopathy. J Natl Med Assoc 1991; 83(11) 949-950

[64] Coughlin SS, Labenberg JR, Tefft MC. Black-white differences in idiopathic dilated cardiomyopathy: the Washington DC dilated Cardiomyopathy Study. Epidemiology 1993; 4(02) 165-172

[65] Can AD, Coughlin SS. Addressing health disparities in idiopathic dilated cardiomyopathy. Jacobs J Community Med 2017; 3(01) 026

[66] Christensen S, Mogelvang R, Heitmann M, Prescott E. Level of education and risk of heart failure: a prospective cohort study with echocardiography evaluation. Eur Heart J 2011; 32(04) 450-458

[67] Schultz WM, Kelli HM, Lisko JC.et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation 2018; 137(20) 2166-2178

[68] Thomas A, Papoutsidakis N, Spatz E.et al. Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system. J Am Heart Assoc 2020; 9(03) e014095

[69] Brown KN.et al. Restrictive cardiomyopathy. In: StatPearls. Treasure Island (FL):: StatPearls Publishing LLC;; 2023

[70] Srivastava S, Yavari M, Al-Abcha A, Banga S, Abela G. Ventricular non-compaction review. Heart Fail Rev 2022; 27(04) 1063-1076

[71] Wadhera RK, Joynt KE. Insurance and cardiovascular health: time for evidence to trump politics. Circulation 2017; 135(21) 1988-1990

[72] Metayer C, Coughlin SS, McCarthy EP. Marital status as a predictor of survival in idiopathic dilated cardiomyopathy: the Washington, DC dilated cardiomyopathy study. Eur J Epidemiol 1996; 12(06) 573-582

[73] Ingles J, Johnson R, Sarina T.et al. Social determinants of health in the setting of hypertrophic cardiomyopathy. Int J Cardiol 2015; 184: 743-749

[74] Musunuru K, Hershberger RE, Day SM.et al; American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ Genom Precis Med 2020; 13(04) e000067

[75] Shaboodien G, Spracklen TF, Kamuli S, Ndibangwi P, Van Niekerk C, Ntusi NAB. Genetics of inherited cardiomyopathies in Africa. Cardiovasc Diagn Ther 2020; 10(02) 262-278

[76] Stafford F, Krishnan N, Richardson E.et al. The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic. Genome Med 2022; 14(01) 145

[77] Dellefave-Castillo LM, Cirino AL, Callis TE.et al. Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing. JAMA Cardiol 2022; 7(09) 966-974

[78] Christiaans I, Kok TM, van Langen IM.et al. Obtaining insurance after DNA diagnostics: a survey among hypertrophic cardiomyopathy mutation carriers. Eur J Hum Genet 2010; 18(02) 251-253

[79] Spoonamore KG, Johnson NM. Who pays? Coverage challenges for cardiovascular genetic testing in U.S. patients. Front Cardiovasc Med 2016; 3: 14

[80] Christian S, Cirino A, Hansen B.et al. Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: a systematic review and meta-analysis. Open Heart 2022; 9(01) e001815

[81] Hershberger RE, Givertz MM, Ho CY.et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail 2018; 24(05) 281-302

[82] Kontorovich AR. Approaches to genetic screening in cardiomyopathies: practical guidance for clinicians. JACC Heart Fail 2023; 11(02) 133-142

[83] Golden SD, Earp JA. Social ecological approaches to individuals and their contexts: twenty years of health education & behavior health promotion interventions. Health Educ Behav 2012; 39(03) 364-372

[84] Saulsberry K, Terry SF. The need to build trust: a perspective on disparities in genetic testing. Genet Test Mol Biomarkers 2013; 17(09) 647-648

[85] Mudd-Martin G, Cirino AL, Barcelona V.et al; American Heart Association Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Considerations for cardiovascular genetic and genomic research with marginalized racial and ethnic groups and indigenous peoples: a scientific statement from the American Heart Association. Circ Genom Precis Med 2021; 14(04) e000084

[86] Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010; 40(04) 360-369

[87] Gopal DP, Chetty U, O'Donnell P, Gajria C, Blackadder-Weinstein J. Implicit bias in healthcare: clinical practice, research and decision making. Future Healthc J 2021; 8(01) 40-48

[88] Dye BA, Duran DG, Murray DM.et al. The importance of evaluating health disparities research. Am J Public Health 2019; 109(S1): S34-S40

RIGHTS & PERMISSIONS

2024 Global Medical Genetics